Will This Analyst Downgrade Hurt Seattle Genetics (SGEN) Stock Today?

NEW YORK (TheStreet) -- Shares of Seattle Genetics  (SGEN) fell 5.29% to $36.36 in morning trading Tuesday after Bank of America/Merrill Lynch  (BAC) downgraded the stock to "underperform" from "neutral."

The firm said Aethera data was not as positive as expected.

Bank of America/Merrill Lynch set a $34 price target on the stock.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Separately, TheStreet Ratings team rates SEATTLE GENETICS INC as a "sell" with a ratings score of D. TheStreet Ratings Team has this to say about their recommendation:

"We rate SEATTLE GENETICS INC (SGEN) a SELL. This is driven by a number of negative factors, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and generally disappointing historical performance in the stock itself."

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

Tuesday Was a 'Prime' Shopping Day for Many Retailers, Not Just Amazon

Tuesday Was a 'Prime' Shopping Day for Many Retailers, Not Just Amazon

Dow Falls, Breaking 5-Day Winning Streak on Beige Book Trade-War Worries

Dow Falls, Breaking 5-Day Winning Streak on Beige Book Trade-War Worries

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

IBM Rides the Cloud to New Heights

IBM Rides the Cloud to New Heights

Jim Cramer on Google Cloud vs. IBM Cloud

Jim Cramer on Google Cloud vs. IBM Cloud